Provided by Tiger Trade Technology Pte. Ltd.

BioRestorative Therapies, Inc.

1.91
+0.02001.06%
Post-market: 1.910.00000.00%19:40 EDT
Volume:18.44K
Turnover:34.77K
Market Cap:2.64M
PE:-0.09
High:1.95
Open:1.92
Low:1.85
Close:1.89
52wk High:34.60
52wk Low:1.75
Shares:1.38M
Float Shares:1.25M
Volume Ratio:0.28
T/O Rate:1.48%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-21.7566
EPS(LYR):-31.6731
ROE:-241.14%
ROA:-118.81%
PB:0.87
PE(LYR):-0.06

Loading ...

Kaos Capital discloses 4.9% stake in BioRestorative Therapies

Reuters
·
May 27

Kaos Capital: Urgently Seeks Meeting With BioRestorative Therapies Board to Discuss Unlocking Shareholder Value

THOMSON REUTERS
·
May 27

Kaos Capital Announces Acquisition of 4.9% Stake in BioRestorative Therapies (Nasdaq: Brtx)

THOMSON REUTERS
·
May 27

BioRestorative Therapies completes Phase 2 dosing of BRTX-100

TIPRANKS
·
May 27

BioRestorative completes Phase 2 dosing of BRTX-100 in chronic lumbar disc disease trial, targets Q2 2027 data

Reuters
·
May 26

BioRestorative Therapies Inc - Topline Phase 2 Data for Brtx-100 Expected in Q2 2027

THOMSON REUTERS
·
May 26

BioRestorative Completes Phase 2 Dosing of BRTX-100, Advancing Lead Regenerative Spine Program Toward 2027 Topline Data

GlobeNewswire
·
May 26

BioRestorative Therapies Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
May 15

BioRestorative Q1 FY26 net loss narrows to $2.15 million; revenue falls 7.32% to $23,170

Reuters
·
May 15

BioRestorative Therapies presents preclinical data on MSC exosome proteomics

TIPRANKS
·
May 14

BioRestorative presents preclinical exosome data at ISCT 2026 annual meeting

Reuters
·
May 13

BioRestorative Therapies Inc expected to post a loss of 20 cents a share - Earnings Preview

Reuters
·
May 08

BioRestorative Therapies reports expanded Phase 2 blinded dataset for BRTX-100

TIPRANKS
·
May 08

BioRestorative reports Phase 2 BRTX-100 data showing 52% hit pain, function endpoint

Reuters
·
May 08

BioRestorative Therapies Inc - 52-Week Cohort Increases to 25 Patients With No Dose-Limiting Toxicity Safety Signals

THOMSON REUTERS
·
May 08

BioRestorative Therapies Inc - 52% of Patients Achieve ≥50% Improvement in Vas Pain and Odi Function at 52 Weeks

THOMSON REUTERS
·
May 08

BioRestorative awards 2025 cash bonuses to CEO, other top executives

Reuters
·
May 02

BioRestorative to present new Phase 2 lumbar disc disease trial data at ISCT 2026

Reuters
·
Apr 30

BioRestorative publishes investor presentation on BRTX-100 stem cell therapy for lumbar disc disease

Reuters
·
Apr 24

BioRestorative Therapies announces partnership with David Goldberg, M.D.

TIPRANKS
·
Apr 21